enzalutamide vs gemfibrozil
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of enzalutamide and gemfibrozil. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
( 7.2 ) 7.1 Effect of Other Drugs on XTANDI Strong CYP2C8 Inhibitors The coadministration of XTANDI with gemfibrozil (a strong CYP2C8 inhibitor) increases plasma concentrations of enzalutamide plus N-desmethyl enzalutamide, which may increase the incidence and severity of adverse reactions of XTANDI.
Xtandi
Lopid
Xtandi contains enzalutamide. It is used to treat prostate cancer that is resistant to certain treatments.
Gemfibrozil is a medicine that helps lower high triglyceride levels in your blood. It can also help reduce the risk of heart disease in some people.
Xtandi is used to treat prostate cancer in men. It is for prostate cancer that keeps growing even when treated with hormone therapy or after surgery. Xtandi can treat prostate cancer that has spread or has not spread.
This medicine is used to treat very high triglyceride levels in adults when diet alone doesn't work. High triglycerides can increase your risk of pancreatitis. Gemfibrozil can also lower the risk of heart disease in some people with specific cholesterol problems.
Xtandi blocks the effect of hormones called androgens, like testosterone. Androgens can help prostate cancer cells grow. By blocking androgens, Xtandi can slow or stop the growth of prostate cancer.
Gemfibrozil belongs to a class of drugs called fibrates. It works by decreasing the amount of triglycerides your body makes. It also helps to increase HDL (good) cholesterol.
- • Muscle or joint pain
- • Feeling tired
- • Hot flashes
- • Constipation
- • Less hungry
- • Upset stomach
- • Indigestion
- • Abdominal pain
- Fatigue 10,159
- Death 7,667
- Malignant Neoplasm Progression 5,409
- Prostatic Specific Antigen Increased 4,295
- Asthenia 4,120
- Nausea 883
- Fatigue 825
- Diarrhoea 726
- Pain 693
- Dizziness 617
Xtandi can cause seizures. If you have a seizure while taking Xtandi, stop taking it permanently. Xtandi can also cause a condition called posterior reversible encephalopathy syndrome (PRES). If you experience PRES, stop taking Xtandi. Xtandi can harm an unborn baby, so men with partners who can get pregnant should use effective birth control during treatment and for 3 months after the last dose.
This medicine may increase your risk of gallbladder problems, including the need for surgery. Before taking gemfibrozil, tell your doctor if you have liver or kidney problems. You should not take this medicine with simvastatin, repaglinide, dasabuvir, or selexipag.
Xtandi is not for use in women. It can cause harm to an unborn baby if taken by a pregnant woman. Men who are taking Xtandi and have partners who can get pregnant should use effective birth control during treatment and for 3 months after the last dose.
Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. It is not known if gemfibrozil can harm your unborn baby. It is also not known if gemfibrozil passes into breast milk.
Also Compare, Nearby Drugs
Compare gemfibrozil with
How to Read This enzalutamide vs gemfibrozil Comparison
enzalutamide is classified in the Androgen Receptor Inhibitor drug class, while gemfibrozil sits within the Fibrate class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, enzalutamide has 31,650 submissions while gemfibrozil has 3,744. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to gemfibrozil blocks the body from breaking down enzalutamide properly. this causes the drug to stay in your blood longer and can increase your risk of having bad side effects.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for enzalutamide or gemfibrozil.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.